Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Gemini in Target Discovery Collaboration

Premium

C

AMBRIDGE, UK--Gemini Genomics, formerly Gemini Holdings, announced that it has entered into a two-year drug target identification collaboration with CuraGen to accelerate drug discovery. CuraGen and Gemini scientists will work together to associate CuraGen's thousands of single-nucleotide polymorphisms with disease traits derived from Gemini's database of clinical populations.

Gemini changed its name late last month to reflect its clinical genomics approach to identifying disease genes.

Separately, CuraGen expanded its drug discovery and pharmacogenomics collaboration with COR Therapeutics of South San Francisco. The companies will use CuraGen's PathCalling proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells.

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.